Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase‐Deficient Gastrointestinal Stromal Tumors
Journal of Surgical Oncology · 2026-06 · 133 (8) · 999-1006
DOI: 10.1002/jso.70259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 20.04.2026. Verfasst von Katherine Y Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego School of Medicine, San Diego, California, USA. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Cytoreduction Surgical Procedures, Succinate Dehydrogenase, Gastrointestinal Neoplasms. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, GIST Research Fund.
Abstract (Originalsprache)
Background and Objectives Succinate dehydrogenase‐deficient (SDH‐deficient) gastrointestinal stromal tumors (GIST) are characterized by variable disease biology with poor responses to traditional tyrosine kinase inhibitors. The role of surgical intervention has been highly debated.
Methods
We performed a single‐institution retrospective analysis of metastatic SDH‐deficient GIST patients who underwent complete (CC‐0) cytoreductive surgery (CRS) from 2017 to 2023. Pathologic‐Peritoneal Cancer Index (P‐PCI) and GIST Metastatectomy‐Surgical Complexity Score (GM‐SCS) were used to quantify complexity. Kaplan‐Meier survival analysis compared time to progression on systemic therapy immediately before CRS (TTP‐1L) and second to last line of systemic therapy before CRS (TTP‐2L) versus time to recurrence (TTR) after CRS.
Results
Nine patients met inclusion criteria. The median age at CRS was 29 years (range: 17–43). Median P‐PCI was 13 (IQR: 10–15) and median GM‐SCS was 19 (IQR: 16–28). Clavien‐Dindo grade ≥ 3 complication rate was 33.3% (3/9) within 90‐days postoperatively. Median TTP‐1L was unreached and median TTP‐2L was 3.4 months (95% CI: 2.5–unreached), as compared to TTR at 26.1 months (95% CI: 15.2–unreached) post CRS ( p ≤ 0.0001).
Conclusions
Patients who underwent CC‐0 CRS achieved prolonged disease control versus prior systemic therapies, suggesting that CRS may be a management option for highly selected SDH‐deficient GIST patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California San Diego School of Medicine, San Diego, California, USA.
- Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California, USA.
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
- Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California, USA.
- Department of Pharmacology, University of California San Diego, San Diego, California, USA.
ORCID-Profile: Jason K Sicklick
Förderung
- NCI NIH HHS
- NIH HHS
- GIST Research Fund
- FDA HHS
- National Institutes of Health
Zitieren
APA
Chen, K. Y., Antkowiak, M., Sharma, A. K., Mallory, R., Burgoyne, A. M., Fanta, P. T., & Sicklick, J. K. (2026). Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase‐Deficient Gastrointestinal Stromal Tumors. Journal of Surgical Oncology, 133(8), 999-1006. https://doi.org/10.1002/jso.70259
Vancouver
Chen KY, Antkowiak M, Sharma AK, Mallory R, Burgoyne AM, Fanta PT, et al. Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase‐Deficient Gastrointestinal Stromal Tumors. Journal of Surgical Oncology. 2026;133(8):999-1006. doi:10.1002/jso.70259
BibTeX
@article{Chen2026,
author = {Chen, Katherine Y and Antkowiak, Mark and Sharma, Ashwyn K and Mallory, Robert and Burgoyne, Adam M and Fanta, Paul T and Sicklick, Jason K},
title = {Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase‐Deficient Gastrointestinal Stromal Tumors},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {133},
number = {8},
pages = {999--1006},
doi = {10.1002/jso.70259}
}
EUVIMED